Breast Cancer Clinical Trials in Canton, Ohio

8 studies are recruiting for breast cancer in Canton, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Aultman Health Foundation, Canton, Ohio

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

2. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

   This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Gabrail Cancer & Research Center, Canton, Ohio

   Locations

   79 in total

   Run by

   BriaCell Therapeutics Corporation

   See if you can join NCT06072612 on ClinicalTrials.gov

3. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

   This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Gabrail Cancer Center, Canton, Ohio

   Locations

   210 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05646862 on ClinicalTrials.gov

4. Integrated Cancer Repository for Cancer Research

   The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

   Stage

   Not phased

   Ages

   19 to 110

   Site

   Aultman Hospital, Canton, Ohio

   Locations

   42 in total

   Run by

   University of Nebraska

   See if you can join NCT02012699 on ClinicalTrials.gov

5. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

   Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Gabrail Cancer Research Center, Canton, Ohio

   Locations

   18 in total

   Run by

   Incyclix Bio

   See if you can join NCT05735080 on ClinicalTrials.gov

6. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

   The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cleveland Clinic Mercy Hospital, Canton, Ohio

   Locations

   7 in total

   Run by

   Carevive Systems, Inc.

   See if you can join NCT05974150 on ClinicalTrials.gov

7. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

   The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Aultman Timken Family Cancer Center, Canton, Ohio

   Locations

   58 in total

   Run by

   Exact Sciences Corporation

   See if you can join NCT06401421 on ClinicalTrials.gov

8. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

   This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Gabrail Cancer Center Research, Canton, Ohio

   Locations

   13 in total

   Run by

   Processa Pharmaceuticals

   See if you can join NCT06568692 on ClinicalTrials.gov